DGAP-News: Evotec SE / Key word(s): Miscellaneous 
Evotec and Chinook Therapeutics enter into strategic collaboration to discover and develop novel precision medicines 
for chronic kidney diseases 
2021-03-01 / 07:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
  . COLLABORATION WILL LEVERAGE THE NURTURE PATIENT BIOBANK AND EVOTEC'S MULTI-OMICS PLATFORMS PANHUNTER AND PANOMICS 
  . EVOTEC AND CHINOOK AIM TO CHARACTERISE MOLECULAR DRIVERS, IDENTIFY AND VALIDATE NOVEL TARGETS AND DRIVE PATIENT 
    STRATIFICATION STRATEGIES IN SELECTED RARE KIDNEY DISEASES 
  . EVOTEC RECEIVES AN UNDISCLOSED UPFRONT AS WELL AS RESEARCH FUNDING AND IS ELIGIBLE TO RECEIVE MILESTONES AND 
    ROYALTIES 
Hamburg, Germany, 01 March 2021: 
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Chinook Therapeutics, Inc. ("Chinook", 
NASDAQ: KDNY) today announced a strategic collaboration focused on the discovery and development of novel precision 
medicine therapies for patients with chronic kidney diseases ("CKD"). Based on Evotec's proprietary comprehensive 
molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook 
and Evotec will jointly identify, characterise and validate novel mechanisms and discover and develop precision 
medicines. 
The collaboration leverages Evotec's proprietary PanOmics platform, which combines enhanced throughput proteomics, high 
throughput transcriptomics and cell imaging with PanHunter, Evotec's unique integrated data analysis platform. In 
addition, Chinook will contribute drug discovery and development programmes to the collaboration targeting rare kidney 
diseases such as IgA nephropathy and glomerular diseases. 
"We are excited to embark on this strategic collaboration with Evotec, the leading drug discovery alliance and 
development partner in nephrology," said Andrew King, Ph.D., Head of Renal Discovery and Translational Medicine at 
Chinook. "Gaining access to the NURTuRE cohort study and other proprietary patient biobanks, along with Evotec's 
multi-omics integration platform, will enable us to define the molecular drivers of kidney diseases, identify novel 
targets for drug development in selected patient sub-populations and continue to build the foundation for our precision 
medicine approach. With a focus on comprehensive molecular disease classification, combined with prospective clinical 
outcomes, Chinook has the opportunity to potentially deliver targeted therapies to the right patient populations." 
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are glad to enter into a discovery and development 
partnership with Chinook Therapeutics, a company specialising in overcoming kidney diseases. CKD is collective term for 
a variety of diseases that cause a gradual loss of kidney function. The diversity in the underlying causes makes this 
area especially favourable for data-driven and systematically personalised approaches. By leveraging our complementary 
platforms, Evotec and Chinook have the best possible starting position to tackle in particular rare forms of CKD with 
the goal to develop disease-modifying therapeutics for underserved patient populations." 
Under the terms of the agreement, Chinook and Evotec will share drug discovery and pre-clinical development 
responsibilities. Chinook will be responsible for clinical development and commercialisation of product candidates 
developed under the collaboration. Evotec will receive an undisclosed upfront payment, research funding, and will be 
eligible to receive progress-dependent milestone payments and tiered royalties on net sales for targets identified 
through the collaboration. 
ABOUT CHINOOK THERAPEUTICS, INC. 
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney 
diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with 
opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, an investigational phase 3 
endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, 
an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In 
addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of 
primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including 
polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA 
sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with 
differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com. 
ABOUT EVOTEC SE 
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative 
product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and 
venture capitalists. We operate worldwide and our more than 3,500 employees provide the highest quality stand-alone and 
integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the 
industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has 
established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies 
as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and 
complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare 
diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned 
product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple 
long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo 
Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us 
on Twitter @Evotec. 
FORWARD-LOOKING STATEMENTS 
Information set forth in this press release contains forward-looking statements, which involve a number of risks and 
uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this 
press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of 
risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ 
materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or 
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our 
expectations or any change in events, conditions or circumstances on which any such statement is based. 
Media Contact Evotec SE: 
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, 
gabriele.hansen@evotec.com 
IR Contact Evotec SE: 
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com 
=---------------------------------------------------------------------------------------------------------------------- 
2021-03-01 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Evotec SE 
              Manfred Eigen Campus / Essener Bogen 7 
              22419 Hamburg 
              Germany 
Phone:        +49 (0)40 560 81-0 
Fax:          +49 (0)40 560 81-222 
E-mail:       info@evotec.com 
Internet:     www.evotec.com 
ISIN:         DE0005664809 
WKN:          566480 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1171812 
 
End of News   DGAP News Service 
=------------ 

1171812 2021-03-01

(END) Dow Jones Newswires

March 01, 2021 01:32 ET (06:32 GMT)